InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Krakonos post# 142804

Sunday, 09/29/2013 11:59:12 AM

Sunday, September 29, 2013 11:59:12 AM

Post# of 346172
but "someone" wants to collect email addresses and send "something" that your antivirus may not pick up on-- I wouldn't send any info

... who was it before that was asking people to email them regarding how many shares each one has to tally up.... minor shift in approach but think of it as that email one gets with those catchy "subject" lines. I would say the closer Peregrine gets, the more "cancer cures" will be floating around but we need to see 1) Who is making that claim 2) MOA 3) Clinical Trial Data 4) Side Affects 5) Does it Target "PS" ? .... and I bet they will not even include the MOA or Side affects ..

Time is closing in...


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News